Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04871789
Status:
UNKNOWN
Last Update Posted:
2021-05-04
First Post:
2021-03-21
Brief Title:
Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19
Sponsor:
Pirogov Russian National Research Medical University
Organization:
Pirogov Russian National Research Medical University
Study Overview
Official Title:
Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19
Status:
UNKNOWN
Status Verified Date:
2021-03
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPTIMIST
Brief Summary:
200 participants should be included in the study There will be three groups 100 participants with a severe course of the disease 3 months ago 50 asymptomatic carriers of coronavirus infection 3 months ago and 50 people who were in close contact with patients with confirmed coronavirus infection 3 months ago but not sick and without antibodies to SARS-CoV-2
The study consists of two visits At the first visit after signing the consent to participate in the study a screening examination will be performed to assess the criteria for inclusion and exclusion in the study
At the second visit patients who meet the inclusion criteria and do not have exclusion criteria will undergo clinical and instrumental examination and biological samples will be collected for laboratory testing
The aim of the study is to determine the most significant clinical and laboratory markers of the severity of the outcomes in the period of convalescence of the new coronavirus infection COVID-19 Clinical and laboratory indicators the number and severity of signs of postcovid syndrome as well as pathological changes in lung tissue according to CT data in the group with covid pneumonia and indicators of immune status hemostasis endothelial dysfunction inflammation metabolism will be assessed
The study consists of two visits At the first visit after signing the consent to participate in the study a screening examination will be performed to assess the criteria for inclusion and exclusion in the study
At the second visit patients who meet the inclusion criteria and do not have exclusion criteria will undergo clinical and instrumental examination and biological samples will be collected for laboratory testing
The aim of the study is to determine the most significant clinical and laboratory markers of the severity of the outcomes in the period of convalescence of the new coronavirus infection COVID-19 Clinical and laboratory indicators the number and severity of signs of postcovid syndrome as well as pathological changes in lung tissue according to CT data in the group with covid pneumonia and indicators of immune status hemostasis endothelial dysfunction inflammation metabolism will be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None